Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in SCLC
NCT04996771Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in small cell lung cancer (SCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
surufatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04996771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996771.